Emcure Pharmaceuticals has launched its IPO valued at ₹1,952.03 crores. Today is the final day of bidding for the IPO. It consists of a fresh issue of 0.79 crore shares aggregating to ₹800 crore and an offer for sale of 1.14 crore shares aggregating to ₹1,152.03 crore.

Emcure Pharmaceuticals IPO Subscription Status

The IPO of Emcure Pharmaceuticals has seen a strong response from investors across categories. As of 12:45 p.m. on July 5, the IPO has been subscribed 11 times. The retail individual investors (RIIs) segment saw a subscription of 5.27 times, while the non-institutional investors (NII) segment was subscribed 30.85 times. The Qualified Institutional Buyers (QIBs) segment was subscribed 6.38 times.

See Also: The Royal Family That Still Owns 1 Tata Sons Share Gifted By JRD Tata

Emcure Pharmaceuticals IPO GMP

The Emcure IPO GMP is currently reported at ₹345. This is a jump from the ₹335 reported yesterday. With the upper price band of the IPO at ₹1,008, the stock is likely to list at ₹1,353, indicating a premium of around 34.23% on the listing. However, it's crucial to remember that while GMPs can provide some insight into market sentiment towards an IPO, they are not always a reliable predictor of the stock's performance upon listing.

Emcure Pharmaceuticals IPO Details

The Emcure IPO price band is set at ₹960 to ₹1,008 per share, with a minimum lot size for an application being 14 shares. 

The allotment for the Emcure Pharma IPO is expected to be finalized on Monday, July 8, 2024. Emcure Pharma IPO will list on BSE, NSE with tentative listing date fixed as Wednesday, July 10, 2024.

Read Next: FPIs Pump ₹10, 910 Cr In Financials And Auto Dump Power And It In June